Tinodasertib
产品说明书
 |
同义名 : | Etc-206;AUM 001;ETC-1907206 |
| CAS号 : | 1464151-33-4 | |
| 货号 : | A229094 | |
| 分子式 : | C25H20N4O2 | |
| 纯度 : | 97% | |
| 分子量 : | 408.452 | |
| MDL号 : | MFCD31692387 | |
| 存储条件： |
Pure form Keep in dark place,Inert atmosphere,Room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(122.41 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | ETC-206 is a selective MNK1 and MNK2 inhibitor with IC50s of 64 nM and 86 nM, respectively. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03414450 | Ph+ Acute Lymphoblastic Leukem... 展开 >>ia (Ph+ALL) Ph- Acute Lymphoblastic Leukemia (Ph-ALL) Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+) 收起 << | Phase 1 | Withdrawn(Withdrawal requested... 展开 >> by D3) 收起 << | February 2023 | United States, Georgia ... 展开 >> Winship Cancer Institute, Emory University Atlanta, Georgia, United States, 30322 United States, Maryland The Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20874 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Singapore Singapore General Hospital Singapore, Singapore, 169608 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.45mL 0.49mL 0.24mL |
12.24mL 2.45mL 1.22mL |
24.48mL 4.90mL 2.45mL |
